Non-Insulin Therapies for Diabetes Market Size, Share Analysis Forecast 2022-2028

Industry Insights

[205+ Pages Report] According to Facts and Factors, the size of the global non-insulin therapies for diabetes market was worth around USD 62,011 million in 2020 and is predicted to grow to around USD 104,863 million by 2028 with a compound annual growth rate (CAGR) of roughly 6.29% between 2021 and 2028. The report analyses the non-insulin therapies for diabetes market’s drivers and restraints, as well as the impact they have on-demand throughout the projection period. In addition, the report examines global opportunities in the global non-insulin therapies for diabetes market

Market Overview

Diabetes affects more than 30 million people in the United States, or around one out of every ten people, according to the Centre for Disease Control and Prevention (CDC). Type 2 diabetes affects 90–95 percent of these people. In type 2 diabetes patients, the body either does not produce enough insulin or is unable to effectively utilize the insulin it produces. Non-insulin therapies are mostly used for the treatment of type 2 diabetes. Non-insulin-based medications use alternative mechanisms of action to lower blood glucose levels and keep them stable for optimal glycemic control.

The insulin category accounts for a large portion of the market in terms of pharmaceuticals. Insulin is required by about 100 million people worldwide, including all patients with Type 1 diabetes and between 10% and 25% of people with Type 2 diabetes.

Growth Drivers

The growing global incidence and prevalence of diabetes are expected to fuel the development of global non-insulin therapies for diabetes market. As per the International Diabetes Federation's Diabetes Atlas 2017, the overall prevalence of diabetic individuals was 425 million, with type 2 diabetes accounting for the vast majority. Non-insulin treatments are most commonly used in type 2 diabetes, which accounts for a sizable proportion of all diabetes cases globally. According to the WHO 2017 report, diabetes is one of the top three causes of death among non-communicable diseases worldwide. This is the primary factor driving the growth of the worldwide non-insulin therapies for diabetes market.

The global non-insulin therapies for diabetes market is growing due to the rising demand for combination therapy and significant improvements in diabetes. For the treatment of type 2 diabetes, combination therapies such as the administration of anti-hyperglycemic medications alone or in addition with insulin are administered. Moreover, on the demand side, the rising number of individuals with type 2 diabetes is the key driver for the global adoption of various non-insulin therapies.

Established players, on the other hand, are putting modern technologies into their products. These technologies can anticipate, monitor, and adjust to the user's needs. These technological advancements give producers a competitive advantage over their competitors, allowing them to maintain a hold on the global market for non-insulin therapies for diabetes.

Report Scope

Regional Landscape

The North American market is expected to generate roughly USD 35,080 million in revenue by the end of the forecast period. The enormous deployment of non-insulin therapy for treating diabetes in nations like the United States is credited with the market's expansion in North America.

According to the International Diabetes Federation (IDF), the United States saw roughly 17,100 new cases of diabetes in 2017. Due to the rising diabetes burden in China and India, which together have over 180 million diabetic patients, Asia Pacific is one of the most lucrative regions. According to the American Diabetes Association (ADA), between 2000 and 2035, the incidence of type 2 diabetes in South Asia is expected to rise by more than 150%.

Recent Development

Players are using strategies like partnerships, collaborations, and mergers to combat the competitive and fragmented structure of the global non-insulin therapies for diabetes market. Players can use these techniques to expand their business globally. Furthermore, these tactics allow businesses to reach out to previously untapped markets that can be profitable. These tactics also enable firms to gather resources that will help them sustain and succeed in the global non-insulin therapies for diabetes market.

Competitive Landscape

Some of the key players operating in the global non-insulin therapies for diabetes market are:

• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb
• Novo Nordisk
• GlaxoSmithKline
• F. Hoffmann-La Roche Ltd.
• Janssen Pharmaceuticals
• AstraZeneca
• Merck and Company
• Sanofi Aventis
• Eli Lilly and Company
• Pfizer
• Novartis AG
• Takeda Pharmaceuticals

The global non-insulin therapies for diabetes market is segmented as follows:

By Product Type Segment Analysis

• Oral
• Injectable

By Distributor Segment Analysis

• Retail Pharmacies
• Hospital Pharmacy
• Online Pharmacy
• Others

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Reunion
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Southeast Asia
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America